PL2976106T3 - Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor - Google Patents

Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor

Info

Publication number
PL2976106T3
PL2976106T3 PL14715440T PL14715440T PL2976106T3 PL 2976106 T3 PL2976106 T3 PL 2976106T3 PL 14715440 T PL14715440 T PL 14715440T PL 14715440 T PL14715440 T PL 14715440T PL 2976106 T3 PL2976106 T3 PL 2976106T3
Authority
PL
Poland
Prior art keywords
inhibitor
combination therapy
raf
raf inhibitor
therapy
Prior art date
Application number
PL14715440T
Other languages
English (en)
Inventor
Giordano Caponigro
Darrin Stuart
Laure DE PARSEVAL
Original Assignee
Array Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50439443&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2976106(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc. filed Critical Array Biopharma Inc.
Publication of PL2976106T3 publication Critical patent/PL2976106T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL14715440T 2013-03-21 2014-03-19 Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor PL2976106T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361804056P 2013-03-21 2013-03-21
EP14715440.5A EP2976106B1 (en) 2013-03-21 2014-03-19 Combination therapy comprising a b-raf inhibitor and a second inhibitor
PCT/IB2014/059975 WO2014147573A2 (en) 2013-03-21 2014-03-19 Combination therapy

Publications (1)

Publication Number Publication Date
PL2976106T3 true PL2976106T3 (pl) 2021-10-25

Family

ID=50439443

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14715440T PL2976106T3 (pl) 2013-03-21 2014-03-19 Terapia kombinowana obejmująca inhibitor B-Raf i drugi inhibitor

Country Status (33)

Country Link
US (3) US9913844B2 (pl)
EP (1) EP2976106B1 (pl)
JP (2) JP6449234B2 (pl)
KR (2) KR102446839B1 (pl)
CN (2) CN105209073A (pl)
AR (1) AR095699A1 (pl)
AU (1) AU2014233805B2 (pl)
BR (1) BR112015023483B8 (pl)
CA (1) CA2907704C (pl)
CL (2) CL2015002807A1 (pl)
CY (1) CY1124776T1 (pl)
DK (1) DK2976106T3 (pl)
EA (1) EA201591842A1 (pl)
ES (1) ES2870716T3 (pl)
GT (1) GT201500249A (pl)
HU (1) HUE055072T2 (pl)
IL (2) IL241188B (pl)
JO (1) JOP20140128B1 (pl)
MA (2) MA38522A1 (pl)
MX (1) MX374246B (pl)
MY (1) MY181085A (pl)
NZ (1) NZ712184A (pl)
PE (1) PE20151785A1 (pl)
PH (1) PH12015502040A1 (pl)
PL (1) PL2976106T3 (pl)
PT (1) PT2976106T (pl)
SG (2) SG10201906270VA (pl)
SI (1) SI2976106T1 (pl)
TN (1) TN2015000389A1 (pl)
TW (1) TWI603734B (pl)
UA (1) UA118846C2 (pl)
WO (1) WO2014147573A2 (pl)
ZA (1) ZA201800424B (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38522A1 (fr) 2013-03-21 2017-10-31 Novartis Ag Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
WO2015191996A1 (en) * 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
CN105753869B (zh) * 2015-04-01 2018-09-25 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
CN116271056A (zh) * 2015-04-16 2023-06-23 日东电工株式会社 针对具有braf基因突变的细胞的细胞死亡诱导试剂、该细胞的增殖抑制试剂及用于治疗由该细胞的增殖异常导致的疾病的医药组合物
CN107530292B (zh) * 2015-04-16 2022-11-01 诺华股份有限公司 瑞博西尼片剂
US9814714B2 (en) * 2015-05-22 2017-11-14 Plexxikon Inc. Kinase modulation, and indications therefor
CN105732642B (zh) * 2015-11-18 2018-09-25 苏州晶云药物科技有限公司 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
AU2017219834B2 (en) * 2016-02-19 2022-06-30 Assistance Publique-Hôpitaux De Paris (Aphp) BYL719 (Alpelisib) for use in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS - CLOVES syndrome)
FI3463345T3 (fi) 2016-06-03 2023-01-31 Farmaseuttisia yhdistelmiä
CN107058565A (zh) * 2016-08-31 2017-08-18 郭军 肢端型黑色素瘤的诊断和治疗
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
KR20190103156A (ko) 2016-12-20 2019-09-04 에테하 취리히 암에서 비-유전적 약물 내성 프로그램을 표적으로 하는 약물의 동정
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP3624896A4 (en) * 2017-05-16 2021-03-31 Biomed Valley Discoveries, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF CANCER WITH ATYPICAL BRAF MUTATIONS
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3109605A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
WO2023212071A1 (en) * 2022-04-26 2023-11-02 Beigene Switzerland Gmbh Combination and the use thereof
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2023240178A1 (en) * 2022-06-08 2023-12-14 Mapkure, Llc Methods of treating cancer with a b-raf inhibitor
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
KR100984595B1 (ko) 2002-03-13 2010-09-30 어레이 바이오파마 인크. Ｍｅｋ 억제제로서의 ｎ3 알킬화 벤즈이미다졸 유도체
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US20060134068A1 (en) 2004-11-09 2006-06-22 Mount Sinai School Of Medicine Of New York University Treatment of cancer by simultaneous inhibiton of BRAF and restoration or mimicry of p16INK4A activity
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
KR20140091718A (ko) * 2006-11-20 2014-07-22 노파르티스 아게 2-메틸-2-［4-(3-메틸-2-옥소-8-퀴놀린-3-일-2,3-디히드로-이미다조［4,5-ｃ］퀴놀린-1-일)-페닐］-프로피오니트릴의 염 및 결정 형태
TWI472529B (zh) * 2008-05-21 2015-02-11 Incyte Corp ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2488184A4 (en) 2009-10-12 2013-04-24 Glaxosmithkline Llc COMBINATION
TWI480276B (zh) * 2010-08-27 2015-04-11 Irm Llc 作為蛋白質激酶抑制劑之化合物及組合物
AU2011329666A1 (en) * 2010-11-19 2013-05-30 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with BRaf inhibitor
US20130004481A1 (en) 2011-01-12 2013-01-03 Boehringer Ingelheim International Gmbh Anticancer therapy
WO2012145503A1 (en) * 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
WO2012178038A1 (en) 2011-06-24 2012-12-27 The Broad Institute, Inc. Methods of treating cancer
EP2570127A1 (en) 2011-09-16 2013-03-20 Sanofi Compositions and methods for treating cancer using PI3KB beta inhibitor and MAPK pathway inhibitor, including MEK and RAF inhibitors
SG11201400724SA (en) * 2011-09-19 2014-04-28 Genentech Inc Combination treatments comprising c-met antagonists and b-raf antagonists
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
JP6342396B2 (ja) 2012-08-07 2018-06-13 ノバルティス アーゲー Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
MA38522A1 (fr) 2013-03-21 2017-10-31 Novartis Ag Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.

Also Published As

Publication number Publication date
SI2976106T1 (sl) 2021-08-31
CA2907704A1 (en) 2014-09-25
CN105209073A (zh) 2015-12-30
MA44934A1 (fr) 2020-01-31
US20180221370A1 (en) 2018-08-09
IL272921B2 (en) 2023-02-01
TW201440770A (zh) 2014-11-01
WO2014147573A2 (en) 2014-09-25
SG10201906270VA (en) 2019-08-27
HK1214135A1 (en) 2016-07-22
IL241188A0 (en) 2015-11-30
JOP20140128B1 (ar) 2021-08-17
PH12015502040B1 (en) 2016-01-18
CA2907704C (en) 2023-01-10
KR102446839B1 (ko) 2022-09-23
JP6742391B2 (ja) 2020-08-19
TWI603734B (zh) 2017-11-01
MA38522A1 (fr) 2017-10-31
JP2019055978A (ja) 2019-04-11
AU2014233805A1 (en) 2015-10-01
MA44934B1 (fr) 2021-11-30
BR112015023483A2 (pt) 2017-07-18
MX374246B (es) 2025-03-05
PH12015502040A1 (en) 2016-01-18
NZ712184A (en) 2020-01-31
CL2018001371A1 (es) 2018-09-07
IL272921B (en) 2022-10-01
TN2015000389A1 (en) 2017-01-03
UA118846C2 (uk) 2019-03-25
MY181085A (en) 2020-12-17
EP2976106A2 (en) 2016-01-27
KR20150132205A (ko) 2015-11-25
GT201500249A (es) 2017-09-01
IL272921A (en) 2020-04-30
PE20151785A1 (es) 2015-12-20
US9913844B2 (en) 2018-03-13
ES2870716T3 (es) 2021-10-27
AR095699A1 (es) 2015-11-04
WO2014147573A3 (en) 2014-12-11
US10548894B2 (en) 2020-02-04
MX2015013466A (es) 2016-06-21
JP6449234B2 (ja) 2019-01-09
BR112015023483B8 (pt) 2023-01-31
PT2976106T (pt) 2021-05-26
SG11201507730UA (en) 2015-10-29
BR112015023483B1 (pt) 2022-07-19
KR102258698B1 (ko) 2021-06-01
BR112015023483A8 (pt) 2019-12-03
CL2015002807A1 (es) 2016-05-13
CN112641787A (zh) 2021-04-13
KR20210110794A (ko) 2021-09-09
US20200246338A1 (en) 2020-08-06
EA201591842A1 (ru) 2016-01-29
CY1124776T1 (el) 2022-11-25
NZ751830A (en) 2020-09-25
ZA201800424B (en) 2022-10-26
IL241188B (en) 2021-02-28
EP2976106B1 (en) 2021-04-14
US20160296520A1 (en) 2016-10-13
DK2976106T3 (da) 2021-06-14
AU2014233805B2 (en) 2018-10-18
HUE055072T2 (hu) 2021-10-28
JP2016522160A (ja) 2016-07-28

Similar Documents

Publication Publication Date Title
IL272921B (en) Combined treatment including a b-raf inhibitor and a second inhibitor
IL276113B (en) Electronic smoking part and electronic smoking device
IL267681B (en) Selective grp94 inhibitors and uses thereof
DK3290407T3 (da) Bromodomæneinhibitorer
IL240239A0 (en) erk inhibitors and their uses
DK3043784T3 (da) Arylethere og anvendelser deraf
ZA201504902B (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
HUE039504T2 (hu) Kináz inhibitor és alkalmazása
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
EP2949343A4 (en) THREE-TONE CONNEXONE AND USE THEREOF
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
EP2953116A4 (en) Display apparatus and device
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
PL3013366T3 (pl) Terapia skojarzona z zastosowaniem inhibitora czynnika xii i inhibitora c1
PL2991633T3 (pl) Terapia bakteriofagami
DK3068505T3 (da) Spillesystem og -fremgangsmåde
DE112014002764A5 (de) Schuh und Schuhset
EP3051144A4 (en) COMPRESSORS AND CHARGERS
IL240324B (en) Actuator and dispensing apparatus
FR3007291B1 (fr) Composition cicatrisante et utlisation
TH1501000566A (th) ตัวยับยั้งนีพริไลซิน
TH1401007295A (th) ตัวยับยั้งนีพริไลซิน